TP53 and breast carcinoma: We then confirmed our findings using the muTarget tool [86] to investigate the effect of mutations in the TP53 coding region (i.e., our input genotype) on downstream gene expression in a sample set comprising 305 TP53-mutant and 674 TP53-wild-type breast cancers.